Biocon starts clinical study to evaluate efficacy of Itolizumab PTI Dec 16, 2022 This is a phase-II randomised, double-blind, parallel-group, placebo and active-controlled (adalimumab), two-treatment period…
Biocon and Equillium expand exclusive licensing agreement for Itolizumab to include Australia and… EP News Bureau Dec 13, 2019 Equillium had originally secured exclusive rights to develop and commercialize Biocon’s novel biologic, itolizumab, for the US and…
